Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• ARCHIMED agreed to acquire Esperion in a deal valuing the company at about $1.1 billion, with shareholders to receive $3.16 per share in cash plus the right to participate in up to $100 million of contingent milestone payments.
• Multiple shareholder‑rights law firms have opened investigations alleging shareholders may not be receiving a fair price, which could lead to litigation, a negotiated price revision, or delays to the deal closing.
• Seven analysts give an average recommendation of Moderate Buy and a one‑year price target of $5.54, though several analysts’ targets (including HC Wainwright’s $3.16) match the deal price, implying limited upside if the transaction proceeds as offered.

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $5.54.

Several equities analysts recently issued reports on the company. HC Wainwright restated a "neutral" rating and set a $3.16 price target on shares of Esperion Therapeutics in a research report on Friday. Wall Street Zen upgraded Esperion Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. Needham & Company LLC lifted their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday, March 3rd. Finally, Citizens Jmp raised their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the company a "market outperform" rating in a research note on Friday, March 13th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ESPR. DHJJ Financial Advisors Ltd. raised its stake in Esperion Therapeutics by 209.2% during the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 6,380 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics during the second quarter valued at $25,000. Vanguard Personalized Indexing Management LLC purchased a new position in Esperion Therapeutics during the third quarter valued at $29,000. R Squared Ltd purchased a new position in shares of Esperion Therapeutics in the third quarter worth $33,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of Esperion Therapeutics in the fourth quarter worth $35,000. Hedge funds and other institutional investors own 47.39% of the company's stock.

Esperion Therapeutics News Roundup

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Archimed agreed to acquire Esperion in a deal valuing the company at as much as ~$1.1 billion; shareholders are to receive $3.16 per share in cash plus the right to participate in up to $100 million of contingent milestone payments — the bid is the primary catalyst lifting the stock. Article Title Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a "neutral" rating and set a $3.16 price target — the PT matches the deal cash price, effectively signaling analyst alignment with the offer price but leaving little upside under the transaction. Article Title
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement for "news pending," consistent with a material corporate event; halts are routine but can compress post‑halt volatility. (Internal trading halt notice)
• Neutral Sentiment: Unusual options activity: roughly 7,568 calls were bought — about a 212% increase versus typical daily call volume — indicating speculative or arbitrage positioning around the deal. This can amplify intraday moves but doesn’t change deal economics. (Options flow report)
• Negative Sentiment: Multiple shareholder‑rights law firms (Monteverde & Associates/M&A Class Action Firm, Ademi LLP, and Halper Sadeh LLC) have opened investigations alleging Esperion shareholders may not be receiving a fair price, which could lead to litigation, a negotiated price revision, or delays to closing. Article Title Article Title Article Title

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $3.11 on Friday. The stock's 50-day simple moving average is $2.55 and its 200 day simple moving average is $3.07. The stock has a market capitalization of $800.53 million, a price-to-earnings ratio of -18.29, a price-to-earnings-growth ratio of 1.62 and a beta of 1.17. Esperion Therapeutics has a 52-week low of $0.69 and a 52-week high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.23 by ($0.01). The business had revenue of $168.45 million during the quarter, compared to analyst estimates of $165.12 million. On average, research analysts forecast that Esperion Therapeutics will post 0.05 earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.